This Epkinly market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to increased healthcare awareness, enhanced regulatory support, a vulnerable pediatric population, a rising prevalence of cancer, and a growing incidence of lung cancer.
The projected growth for the forecast period is driven by increased research and development initiatives, a rising adoption of advanced therapies, heightened healthcare awareness, growing investments, and the expanding use of sophisticated treatment options. Key trends in the forecast period include the launch of new drugs, increased R&D efforts focused on non-Hodgkin lymphoma treatments, innovative therapeutic approaches, and technological advancements in treatment and care.
The growing demand for targeted therapies is expected to drive the expansion of the epkinly market in the future. Targeted therapies are becoming more popular due to their precision in treating diseases, particularly cancers, by blocking specific molecules that drive disease progression. These therapies offer more effective and personalized treatments with fewer side effects compared to traditional treatments. Epkinly (epcoritamab) is a targeted therapy used for relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It works by binding CD3 on T cells and CD20 on B cells, directing the immune system to destroy cancerous B cells. The rising demand for such targeted therapies is expected to propel the growth of the epkinly market.
A significant trend driving growth in the epkinly market is the approval of innovative therapies, particularly bispecific antibody therapies. Bispecific antibodies are engineered to bind to two different antigens or targets simultaneously, making them more effective in treating diseases such as lymphoma. In June 2024, AbbVie Inc. received FDA approval for Epkinly (epcoritamab-bysp), the first bispecific antibody therapy for adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This therapy demonstrated an impressive 82% overall response rate in clinical trials, making it a breakthrough option for patients who have limited alternatives. The approval of Epkinly marks an important step forward in the management of follicular lymphoma, offering hope for better patient outcomes.
In June 2024, AbbVie Inc., a U.S.-based biotechnology company, entered into a partnership with Genmab A/S, a Denmark-based biotechnology firm, to jointly develop and commercialize innovative bispecific antibody therapies, including Epkinly (epcoritamab). This collaboration leverages Genmab's cutting-edge antibody technology alongside AbbVie's extensive clinical expertise to advance new treatment options. Epkinly, a bispecific antibody, is one of the key products in this partnership, aimed at treating relapsed or refractory B-cell non-Hodgkin lymphoma and other cancers. The alliance between AbbVie and Genmab is expected to accelerate the development of new immunotherapies, expanding treatment possibilities for patients with challenging cancers and enhancing the global presence of bispecific antibody therapies.
Major companies operating in the epkinly market are AbbVie Inc. and Genmab A/S.
North America was the largest region in the epkinly market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in epkinly report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the epkinly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Epkinly (epcoritamab) is a monoclonal antibody used to treat certain types of cancer, particularly relapsed or refractory B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and other non-Hodgkin lymphoma (NHL) subtypes. It works by targeting and binding to CD3, a protein found on T cells, and CD20, a protein found on B cells, which enhances the immune system’s ability to recognize and destroy cancerous cells.
The primary indications for epkinly include relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), and indolent lymphoma. Relapsed or refractory DLBCL refers to cases where the disease returns after initial treatment. Epkinly is administered through intravenous (IV) or subcutaneous (SC) routes and is distributed via hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies.
The epkinly market research report is one of a series of new reports that provides epkinly market statistics, including epkinly industry global market size, regional shares, competitors with an epkinly market share, detailed epkinly market segments, market trends and opportunities, and any further data you may need to thrive in the epkinly industry. This epkinly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The epkinly market consists of sales of products including rituxan (rituximab), polivy (polatuzumab vedotin), kymriah (tisagenlecleucel), yescarta (axicabtagene ciloleucel), and gazyva (obinutuzumab). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to increased healthcare awareness, enhanced regulatory support, a vulnerable pediatric population, a rising prevalence of cancer, and a growing incidence of lung cancer.
The projected growth for the forecast period is driven by increased research and development initiatives, a rising adoption of advanced therapies, heightened healthcare awareness, growing investments, and the expanding use of sophisticated treatment options. Key trends in the forecast period include the launch of new drugs, increased R&D efforts focused on non-Hodgkin lymphoma treatments, innovative therapeutic approaches, and technological advancements in treatment and care.
The growing demand for targeted therapies is expected to drive the expansion of the epkinly market in the future. Targeted therapies are becoming more popular due to their precision in treating diseases, particularly cancers, by blocking specific molecules that drive disease progression. These therapies offer more effective and personalized treatments with fewer side effects compared to traditional treatments. Epkinly (epcoritamab) is a targeted therapy used for relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It works by binding CD3 on T cells and CD20 on B cells, directing the immune system to destroy cancerous B cells. The rising demand for such targeted therapies is expected to propel the growth of the epkinly market.
A significant trend driving growth in the epkinly market is the approval of innovative therapies, particularly bispecific antibody therapies. Bispecific antibodies are engineered to bind to two different antigens or targets simultaneously, making them more effective in treating diseases such as lymphoma. In June 2024, AbbVie Inc. received FDA approval for Epkinly (epcoritamab-bysp), the first bispecific antibody therapy for adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This therapy demonstrated an impressive 82% overall response rate in clinical trials, making it a breakthrough option for patients who have limited alternatives. The approval of Epkinly marks an important step forward in the management of follicular lymphoma, offering hope for better patient outcomes.
In June 2024, AbbVie Inc., a U.S.-based biotechnology company, entered into a partnership with Genmab A/S, a Denmark-based biotechnology firm, to jointly develop and commercialize innovative bispecific antibody therapies, including Epkinly (epcoritamab). This collaboration leverages Genmab's cutting-edge antibody technology alongside AbbVie's extensive clinical expertise to advance new treatment options. Epkinly, a bispecific antibody, is one of the key products in this partnership, aimed at treating relapsed or refractory B-cell non-Hodgkin lymphoma and other cancers. The alliance between AbbVie and Genmab is expected to accelerate the development of new immunotherapies, expanding treatment possibilities for patients with challenging cancers and enhancing the global presence of bispecific antibody therapies.
Major companies operating in the epkinly market are AbbVie Inc. and Genmab A/S.
North America was the largest region in the epkinly market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in epkinly report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the epkinly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Epkinly (epcoritamab) is a monoclonal antibody used to treat certain types of cancer, particularly relapsed or refractory B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and other non-Hodgkin lymphoma (NHL) subtypes. It works by targeting and binding to CD3, a protein found on T cells, and CD20, a protein found on B cells, which enhances the immune system’s ability to recognize and destroy cancerous cells.
The primary indications for epkinly include relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), and indolent lymphoma. Relapsed or refractory DLBCL refers to cases where the disease returns after initial treatment. Epkinly is administered through intravenous (IV) or subcutaneous (SC) routes and is distributed via hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies.
The epkinly market research report is one of a series of new reports that provides epkinly market statistics, including epkinly industry global market size, regional shares, competitors with an epkinly market share, detailed epkinly market segments, market trends and opportunities, and any further data you may need to thrive in the epkinly industry. This epkinly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The epkinly market consists of sales of products including rituxan (rituximab), polivy (polatuzumab vedotin), kymriah (tisagenlecleucel), yescarta (axicabtagene ciloleucel), and gazyva (obinutuzumab). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Epkinly Market Characteristics4. Epkinly Market Trends and Strategies5. Epkinly Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Epkinly Pricing Analysis & Forecasts30. Global Epkinly Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Epkinly Market32. Recent Developments in the Epkinly Market
3. Epkinly Market Biologic Drug Characteristics
6. Global Epkinly Growth Analysis and Strategic Analysis Framework
8. Epkinly Market Segmentation
9. Global Epkinly Epidemiology of Clinical Indications
10. Epkinly Market Regional and Country Analysis
11. Asia-Pacific Epkinly Market
12. China Epkinly Market
13. India Epkinly Market
14. Japan Epkinly Market
15. Australia Epkinly Market
16. South Korea Epkinly Market
17. Western Europe Epkinly Market
18. UK Epkinly Market
19. Germany Epkinly Market
20. France Epkinly Market
21. Eastern Europe Epkinly Market
22. North America Epkinly Market
23. USA Epkinly Market
24. Canada Epkinly Market
25. South America Epkinly Market
26. Middle East Epkinly Market
27. Africa Epkinly Market
28. Epkinly Market Competitive Landscape and Company Profiles
29. Global Epkinly Market Pipeline Analysis
33. Epkinly Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Epkinly Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on epkinly market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for epkinly? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The epkinly market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL); High-Grade B-Cell Lymphoma (HGBL); Indolent Lymphoma2) by Route of Administration: Intravenous (IV); Subcutaneous (SC)
3) by Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Specialty Pharmacies; Online Pharmacies
Key Companies Mentioned: AbbVie Inc.; Genmab a/S.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- AbbVie Inc.
- Genmab A/S.
